市場調査レポート
商品コード
1552662

核酸医薬の世界市場:産業分析、規模、シェア、成長、動向、予測、2024-2034年

Nucleic Acid Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


出版日
ページ情報
英文 195 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.11円
核酸医薬の世界市場:産業分析、規模、シェア、成長、動向、予測、2024-2034年
出版日: 2024年07月17日
発行: Transparency Market Research
ページ情報: 英文 195 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

核酸医薬市場- 調査範囲

TMRの調査レポート「核酸医薬の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の核酸医薬市場の収益と予測を提供しています。また、2024年から2034年までの世界の核酸医薬市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、核酸医薬市場を推察しました。

市場スナップショット
2023年の市場規模 60億米ドル
2034年の市場規模 221億米ドル
CAGR 12.8%

当レポートでは、世界の核酸医薬市場の競合情勢について調査しています。世界の核酸医薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の核酸医薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー:世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 国別の規制シナリオ
  • 技術の進歩
  • 償還シナリオ
  • PESTEL分析
  • ポーターのファイブフォース分析
  • 市場への影響分析
  • 投資シナリオ
  • 現在の治療情勢におけるアンメットニーズ

第6章 世界の市場分析と予測:製品別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測:製品別、2020-2034年
    • アンチセンスオリゴヌクレオチド(ASO)
    • RNA干渉(RNAi)
    • RNAアプタマー
  • 製品別の市場の魅力

第7章 世界の市場分析と予測:適応症別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測:適応症別、2020-2034年
    • 自己免疫疾患
    • 感染症
    • 遺伝性疾患
    • がん
    • その他
  • 適応症別の市場の魅力

第8章 世界の市場分析と予測:エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測:エンドユーザー別、2020-2034年
    • 病院
    • 医師の診療所
    • その他
  • エンドユーザー別の市場の魅力

第9章 世界の市場分析と予測:地域別

  • 主な調査結果
  • 市場金額予測:地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場の魅力

第10章 北米の市場分析と予測

  • 米国
  • カナダ

第11章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州

第12章 アジア太平洋地域の市場分析と予測

  • 中国
  • インド
  • 日本
  • オーストラリア・ニュージーランド
  • その他アジア太平洋地域

第13章 ラテンアメリカの市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ

第14章 中東・アフリカの市場分析と予測

  • GCC
  • 南アフリカ
  • その他中東・アフリカ

第15章 競合情勢

  • 市場企業-競合マトリックス(企業階層と規模別)
  • 市場シェア分析企業別(2023)
  • 企業プロファイル
    • Alynylam Pharmaceutials, Inc.
    • BioNTech
    • Ionis Pharmaceuticals, Inc.
    • Moderna
    • Nippon Shinyaku
    • Novartis
    • Pfizer
    • Sarepta Therapeutics
    • Biogen Inc.
    • Genzyme Sanofi
    • Percheron Therapeutics Ltd.
図表

List of Tables

  • Table 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
  • Table 02: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 03: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 4: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Region, 2020-2034
  • Table 5: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 6: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
  • Table 7: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 8: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 9: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
  • Table 11: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 12: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
  • Table 15: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 16: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
  • Table 19: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 20: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Product, 2020-2034
  • Table 23: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 24: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Nucleic Acid Therapeutics Market Size, by Product, 2023
  • Figure 02: Global Nucleic Acid Therapeutics Market share (%), by Product, 2023
  • Figure 03: Global Nucleic Acid Therapeutics Market Size, by Indication, 2023
  • Figure 04: Global Nucleic Acid Therapeutics Market share (%), by Indication, 2023
  • Figure 05: Global Nucleic Acid Therapeutics Market Size, by End-user, 2023
  • Figure 06: Global Nucleic Acid Therapeutics Market share (%), by End-user, 2023
  • Figure 07: Global Nucleic Acid Therapeutics Market, By Region 2023 and 2034
  • Figure 8: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 9: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
  • Figure 10: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023
  • Figure 11: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2034
  • Figure 12: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
  • Figure 13: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Anti-Sense Oligonucleotides (ASO), 2020-2034
  • Figure 14: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Anti-Sense Oligonucleotides (ASO), 2023 and 2034
  • Figure 15: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by RNA Interference (RNAi) , 2020-2034
  • Figure 16: Global Nucleic Acid Therapeutics Market Value Share Analysis, RNA Interference (RNAi) , 2023 and 2034
  • Figure 17: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by RNA Aptamers, 2020-2034
  • Figure 18: Global Nucleic Acid Therapeutics Market Value Share Analysis, by RNA Aptamers, 2023 and 2034
  • Figure 19: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 20: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023
  • Figure 21: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2034
  • Figure 22: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
  • Figure 23: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Autoimmune Disorders (ASO), 2020-2034
  • Figure 24: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Autoimmune Disorders, 2023 and 2034
  • Figure 25: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Infectious Diseases, 2020-2034
  • Figure 26: Global Nucleic Acid Therapeutics Market Value Share Analysis, Infectious Diseases, 2023 and 2034
  • Figure 27: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Genetic Disorders, 2020-2034
  • Figure 28: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Genetic Disorders, 2023 and 2034
  • Figure 29: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Cancer , 2020-2034
  • Figure 30: Global Nucleic Acid Therapeutics Market Value Share Analysis, Cancer , 2023 and 2034
  • Figure 31: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Others, 2020-2034
  • Figure 32: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Others, 2023 and 2034
  • Figure 33: Global Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 34: Global Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023
  • Figure 35: Global Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2034
  • Figure 36: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 37: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Hospitals, 2020-2034
  • Figure 38: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Hospitals, 2023 and 2034
  • Figure 39: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Physicians' Offices , 2020-2034
  • Figure 40: Global Nucleic Acid Therapeutics Market Value Share Analysis, Physicians' Offices , 2023 and 2034
  • Figure 41: Global Nucleic Acid Therapeutics Market Value (US$ Mn), by Others , 2020-2034
  • Figure 42: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Others , 2023 and 2034
  • Figure 43: Global Nucleic Acid Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 44: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 45: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 46: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 47: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country, 2023-2034
  • Figure 48: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
  • Figure 49: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
  • Figure 50: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 51: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
  • Figure 52: North America Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 53: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 54: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 55: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 56: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
  • Figure 57: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
  • Figure 58: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
  • Figure 59: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 60: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
  • Figure 61: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 63: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 64: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 65: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
  • Figure 66: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
  • Figure 67: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
  • Figure 68: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 69: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
  • Figure 70: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 71: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 72: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 73: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 74: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
  • Figure 75: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
  • Figure 76: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
  • Figure 77: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 78: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
  • Figure 79: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 80: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 81: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 82: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 83: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
  • Figure 84: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Product, 2023 and 2034
  • Figure 85: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Product, 2023-2034
  • Figure 86: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 87: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Indication, 2023-2034
  • Figure 88: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 89: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
目次
Product Code: TMRGL86333

Nucleic Acid Therapeutics Market - Scope of Report

TMR's report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nucleic acid therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market.

Market Snapshot
Market Value in 2023US$ 6 Bn
Market Value in 2034US$ 22.1 Bn
CAGR12.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market.

The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report.

Key Questions Answered in Global nucleic acid therapeutics Market Report:

  • What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period?
  • What are the opportunities in the global nucleic acid therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Nucleic Acid Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nucleic Acid Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Regulatory Scenario by Countries
  • 5.3. Technological Advancement
  • 5.4. Reimbursement Scenario
  • 5.5. PESTEL Analysis
  • 5.6. Porter's Five Force Analysis
  • 5.7. Impact Analysis on Market
  • 5.8. Investment Scenario
  • 5.9. Unmet Needs in Current Treatment Landscape

6. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Product, 2020-2034
    • 6.3.1. Anti-Sense Oligonucleotides (ASO)
    • 6.3.2. RNA Interference (RNAi)
    • 6.3.3. RNA Aptamers
  • 6.4. Market Attractiveness By Product

7. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Indication, 2020-2034
    • 7.3.1. Autoimmune Disorders
    • 7.3.2. Infectious Diseases
    • 7.3.3. Genetic Disorders
    • 7.3.4. Cancer
    • 7.3.5. Others
  • 7.4. Market Attractiveness By Indication

8. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By End-user, 2020-2034
    • 8.3.1. Hospitals
    • 8.3.2. Physicians' Offices
    • 8.3.3. Others
  • 8.4. Market Attractiveness By End-user

9. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America Nucleic Acid Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Product, 2020-2034
    • 10.2.1. Anti-Sense Oligonucleotides (ASO)
    • 10.2.2. RNA Interference (RNAi)
    • 10.2.3. RNA Aptamers
  • 10.3. Market Value Forecast By Indication, 2020-2034
    • 10.3.1. Autoimmune Disorders
    • 10.3.2. Infectious Diseases
    • 10.3.3. Genetic Disorders
    • 10.3.4. Cancer
    • 10.3.5. Others
  • 10.4. Market Value Forecast By End-user, 2020-2034
    • 10.4.1. Hospitals
    • 10.4.2. Physicians' Offices
    • 10.4.3. Others
  • 10.5. Market Value Forecast By Country, 2020-2034
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Product
    • 10.6.2. By Indication
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Nucleic Acid Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Product, 2020-2034
    • 11.2.1. Anti-Sense Oligonucleotides (ASO)
    • 11.2.2. RNA Interference (RNAi)
    • 11.2.3. RNA Aptamers
  • 11.3. Market Value Forecast By Indication, 2020-2034
    • 11.3.1. Autoimmune Disorders
    • 11.3.2. Infectious Diseases
    • 11.3.3. Genetic Disorders
    • 11.3.4. Cancer
    • 11.3.5. Others
  • 11.4. Market Value Forecast By End-user, 2020-2034
    • 11.4.1. Hospitals
    • 11.4.2. Physicians' Offices
    • 11.4.3. Others
  • 11.5. Market Value Forecast By Country/Sub-region, 2020-2034
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Product
    • 11.6.2. By Indication
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Product, 2020-2034
    • 12.2.1. Anti-Sense Oligonucleotides (ASO)
    • 12.2.2. RNA Interference (RNAi)
    • 12.2.3. RNA Aptamers
  • 12.3. Market Value Forecast By Indication, 2020-2034
    • 12.3.1. Autoimmune Disorders
    • 12.3.2. Infectious Diseases
    • 12.3.3. Genetic Disorders
    • 12.3.4. Cancer
    • 12.3.5. Others
  • 12.4. Market Value Forecast By End-user, 2020-2034
    • 12.4.1. Hospitals
    • 12.4.2. Physicians' Offices
    • 12.4.3. Others
  • 12.5. Market Value Forecast By Country/Sub-region, 2020-2034
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Product
    • 12.6.2. By Indication
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Product, 2020-2034
    • 13.2.1. Anti-Sense Oligonucleotides (ASO)
    • 13.2.2. RNA Interference (RNAi)
    • 13.2.3. RNA Aptamers
  • 13.3. Market Value Forecast By Indication, 2020-2034
    • 13.3.1. Autoimmune Disorders
    • 13.3.2. Infectious Diseases
    • 13.3.3. Genetic Disorders
    • 13.3.4. Cancer
    • 13.3.5. Others
  • 13.4. Market Value Forecast By End-user, 2020-2034
    • 13.4.1. Hospitals
    • 13.4.2. Physicians' Offices
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Country/Sub-region, 2020-2034
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Product
    • 13.6.2. By Indication
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Product, 2020-2034
    • 14.2.1. Anti-Sense Oligonucleotides (ASO)
    • 14.2.2. RNA Interference (RNAi)
    • 14.2.3. RNA Aptamers
  • 14.3. Market Value Forecast By Indication, 2020-2034
    • 14.3.1. Autoimmune Disorders
    • 14.3.2. Infectious Diseases
    • 14.3.3. Genetic Disorders
    • 14.3.4. Cancer
    • 14.3.5. Others
  • 14.4. Market Value Forecast By End-user, 2020-2034
    • 14.4.1. Hospitals
    • 14.4.2. Physicians' Offices
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Country/Sub-region, 2020-2034
    • 14.5.1. GCC
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Product
    • 14.6.2. By Indication
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Alynylam Pharmaceutials, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. BioNTech
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Ionis Pharmaceuticals, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Moderna
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Nippon Shinyaku
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Novartis
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Sarepta Therapeutics
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Biogen Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Genzyme Sanofi
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Percheron Therapeutics Ltd.
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview